natgillin/translations-raw huggingface dataset:
As there is very limited clinical experience in patients with severe renal impairment (eGFR &lt; 30 ml/min/1.73 m2) (see section 5.1) Neparvis should be used with caution and a starting dose of 24 mg/26 mg twice daily is recommended.
Budući da postoji vrlo ograničeno kliničko iskustvo u bolesnika s teškim oštećenjem bubrega (eGFR &lt; 30 ml/min/1,73 m2) (vidjeti dio 5.1) Neparvis treba primjenjivati s oprezom te se preporučuje početna doza od 24 mg/26 mg dvaput na dan.
As urinary pH rises above 6.5, the renal clearance of free salicylate increases from &lt; 5% to &gt; 80%.
Kad se pH urina poveća iznad 6,5, bubrežni klirens slobodne frakcije salicilata poveća se sa &lt; 5% na &gt; 80%.
As valproate significantly decreases clearance of rufinamide, a lower maximum dose of Inovelon is recommended for patients &lt; 30 kg being co-administered valproate.
Budući da valproat značajno smanjuje klirens rufinamida, u bolesnika s tjelesnom težinom &lt; 30 kg kojima se istovremeno daje valproat preporučuje se niža maksimalna doza Inovelona.
As valproate significantly decreases clearance of rufinamide, a lower maximum dose of Inovelon is recommended for patients &lt; 30 kg being co-administered valproate.
Budući da valproat značajno smanjuje klirens rufinamida, u bolesnika s tjelesnom težinom &lt; 30 kg kojima se istovremeno daje valproat, preporučuje se niža maksimalna doza Inovelona.
As valproate significantly decreases clearance of rufinamide, a lower maximum dose of Inovelon is recommended for patients &lt; 30 kg being co-administered valproate.
Budući da valproat značajno smanjuje klirens rufinamida, u bolesnika s tjelesnom težinom &lt; 30 kg, kojima se istovremeno daje valproat, preporučuje se niža maksimalna doza Inovelona.
As with other beta-lactam antimicrobial agents, the percent time above the minimum inhibitory concentration (MIC) of the infecting organism over the dosing interval (%T &gt; MIC) has been shown to be the parameter that best correlates with the efficacy of ceftaroline.
Kao i kod drugih beta-laktamskih antimikrobnih lijekova, pokazalo se da je postotak vremena iznad minimalne inhibitorne koncentracije (MIK) za uzročnika infekcije tijekom intervala doziranja (%T &gt; MIK) parametar koji najbolje korelira s djelotvornošću ceftarolina.
ASAS 20 responses were improved at Week 16 in both anti-TNFα-naïve patients (68.2% versus 31.1%; p &lt; 0.05) and anti-TNFα-IR patients (50.0% versus 24.1%; p &lt; 0.05) for Cosentyx 150 mg compared with placebo, respectively.
Odgovori ASAS 20 bili su bolji u 16. tjednu i u bolesnika koji nisu ranije primali anti-TNFα (68,2% u odnosu na 31,1%; p &lt; 0,05) i anti-TNFα-NO bolesnika (50,0% u odnosu na 24,1%; p &lt; 0,05) za Cosentyx 150 mg u usporedbi s placebom.
Asia1 Shamir and SAT2 Saudi Arabia
Azija 1 Shamir &amp; SAT2 Saudi Arabia
Aspartate aminotransferase increased (SGOT &gt; 5 times baseline)   * °
Povećana alanin aminotransferaza (SGPT &gt; 5 puta više od početne vrijednosti)   * °
Aspartate aminotransferase increased (SGOT &gt; 5 times baseline)   * °
Povećana aspartat aminotransferaza (SGOT &gt; 5 puta više od početne vrijednosti)   * °
Assess the benefit/risk in patients with lymphocyte counts ≥0.5 x 109/L and &lt; 0.8 x 109/L for more than six months.
Procijenite omjer koristi i rizika u bolesnika s brojem limfocita ≥0,5x109/l i &lt; 0,8x109/l dulje od šest mjeseci.
Assessment of adverse reactions is based on one randomised study (study GS-US-174-0115) in 106 adolescent patients (12 to &lt; 18 years of age) with chronic hepatitis B receiving treatment with tenofovir disoproxil 245 mg (as fumarate) (n = 52) or placebo (n = 54) for 72 weeks.
Nuspojave su se procijenile na temelju jednog randomiziranog ispitivanja (ispitivanje GS-US-174-0115) u 106 adolescentnih pacijenata (u dobi od 12 do &lt; 18 godina) s kroničnim hepatitisom B koji su primali liječenje tenofovirdizoproksilom u dozi od 245 mg (u obliku tenofovirdizoproksilfumarata) (n = 52) ili placebo (n = 54) tijekom 72 tjedna.
Assessment of adverse reactions is based on two randomised trials (studies GS-US-104-0321 and GS-US-104-0352) in 184 HIV-1 infected paediatric patients (aged 2 to &lt; 18 years) who received treatment with tenofovir disoproxil fumarate (n = 93) or placebo/active comparator (n = 91) in combination with other antiretroviral agents for 48 weeks (see section 5.1).
Procjena nuspojava temelji se na dva randomizirana ispitivanja (ispitivanja GS-US-104-0321 i GS-US-104-0352) u 184 pedijatrijskih pacijenata zaraženih virusom HIV-1 (u dobi od 2 do &lt; 18 godina) koji su liječeni tenofovirdizoproksilfumaratom (n = 93) ili placebom/aktivnim komparatorom (n = 91) u kombinaciji s drugim antiretrovirusnim lijekovima tijekom 48 tjedana (vidjeti dio 5.1).
Assessments on remission (DAS28(ESR) &lt; 2.6), Low Disease Activity (DAS28(ESR) ≤3.2) status, ACR50 and ACR 70 by visit demonstrated that Cimzia+MTX treatment led to faster and greater responses than PBO+MTX treatment.
Ocjena remisije (DAS28(ESR) &lt; 2,6), statusa niske aktivnosti bolesti (DAS28(ESR) ≤3,2), odgovora ACR50 i ACR70 po posjetu je pokazala da je liječenje režimom Cimzia+MTX dovelo do bržeg i većeg odgovora nego liječenje režimom placebo+MTX.
associated with alkaline phosphatase &gt; 2.5 × ULN, and bilirubin &gt; 1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated.
Za te bolesnike nema preporuka za smanjenje doze te se docetaksel ne smije primijeniti osim ako to nije striktno indicirano.
AST: &gt; ULN (can be normal or &lt; ULN if total bilirubin is &gt; ULN)
AST: &gt; GGN (može biti normalan ili &lt; GGN ako je ukupni bilirubin &gt; GGN)
At 1 year (week 52), 89% of patients re-randomised to maintenance treatment were PASI 75 responders compared with 63% of patients re-randomised to placebo (treatment withdrawal) (p &lt; 0.001).
U 1. godini (52. tjedan), 89% bolesnika ponovno randomiziranih na održavanje liječenja, imalo je odgovor PASI 75, u usporedbi sa 63% bolesnika ponovno randomiziranih na placebo (prekid liječenja) (p &lt; 0,001).
At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 108 ml in the 6-month study and by 97 ml in the 12-month study compared to placebo (both p &lt; 0.001).
Nakon 12 tjedana (primarna mjera ishoda), Enurev Breezhaler je povećao najniži FEV1 za 108 ml u 6-mjesečnom ispitivanju te za 97 ml u 12-mjesečnom ispitivanju u usporedbi s placebom (oba p &lt; 0,001).
At 12 weeks (primary endpoint), Enurev Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility ( &lt; 5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p &lt; 0.05).
12 tjedana (primarna mjera ishoda), Enurev Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti ( &lt; 5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p &lt; 0,05).
At 12 weeks (primary endpoint), Seebri Breezhaler increased trough FEV1 by 108 ml in the 6-month study and by 97 ml in the 12-month study compared to placebo (both p &lt; 0.001).
Nakon 12 tjedana (primarna mjera ishoda), Seebri Breezhaler je povećao najniži FEV1 za 108 ml u 6-mjesečnom ispitivanju te za 97 ml u 12-mjesečnom ispitivanju u usporedbi s placebom (oba p &lt; 0,001).
At 12 weeks (primary endpoint), Seebri Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility ( &lt; 5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p &lt; 0.05).
12 tjedana (primarna mjera ishoda), Seebri Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti ( &lt; 5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p &lt; 0,05).
At 12 weeks (primary endpoint), Tovanor Breezhaler increased trough FEV1 by 108 ml in the 6-month study and by 97 ml in the 12-month study compared to placebo (both p &lt; 0.001).
Nakon 12 tjedana (primarna mjera ishoda), Tovanor Breezhaler je povećao najniži FEV1 za 108 ml u 6-mjesečnom ispitivanju te za 97 ml u 12-mjesečnom ispitivanju u usporedbi s placebom (oba p &lt; 0,001).
At 12 weeks (primary endpoint), Tovanor Breezhaler increased trough FEV1 by 72 ml in patients with the lowest degree of reversibility ( &lt; 5%) and by 113 ml in those patients with a higher degree of reversibility at baseline (≥5%) compared to placebo (both p &lt; 0.05).
12 tjedana (primarna mjera ishoda), Tovanor Breezhaler povećao je najniži FEV1 za 72 ml u bolesnika s najnižim stupnjem reverzibilnosti ( &lt; 5%) te za 113 ml u onih bolesnika koji su imali viši stupanj reverzibilnosti na početku (≥5%) u usporedbi s placebom (oba p &lt; 0,05).
At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA &lt; 50 copies/ml.
Nakon 24 tjedna iza randomizacije, u ispitivanju TRANxITION, 92,6 % bolesnika na Viramuneu 200 mg s trenutnim oslobađanjem dvaput dnevno ili Viramuneu 400 mg s produljenim oslobađanjem jednom dnevno, i dalje je imalo HIV-1 RNK vrijednosti &lt; 50 kopija/ml.
At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA &lt; 50 copies/ml.
Nakon 24 tjedna iza randomizacije, u ispitivanju TRANxITION, 92,6 % bolesnika na Viramuneu 200 mg s trenutnim oslobađanjem dvaput dnevno odnosno 93,6 % bolesnika na Viramuneu 400 mg s produljenim oslobađanejm jednom dnevno , i dalje je imalo HIV-1 RNK vrijednosti &lt; 50 kopija/ml.
At 24 weeks after randomisation in the TRANxITION study, 92.6 % and 93.6 % of patients receiving Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily, respectively, continued to have HIV-1 RNA &lt; 50 copies/ml.
Nakon 24 tjedna iza randomizacije, u ispitivanju TRANxITION, 92,6 % bolesnika na Viramuneu 200 mg s trenutnim oslobađanjem dvaput dnevno odnosno 93,6 % bolesnika na Viramuneu 400 mg s produljenim oslobađanjem jednom dnevno, i dalje je imalo HIV-1 RNK vrijednosti &lt; 50 kopija/ml.
At 24 weeks, 16 of 23 (70%) adolescents (12 to less than 18 years of age) treated with Tivicay once daily (35 mg n=4, 50 mg n=19) plus OBR achieved viral load &lt; 50 copies/mL.
Nakon 24 tjedna, 16 od 23 (70%) adolescenata (u dobi od 12 do manje od 18 godina) liječenih lijekom Tivicay jedanput na dan (35 mg n=4, 50 mg n=19) u kombinaciji s optimiziranim osnovnim režimom liječenja postiglo je virusno opterećenje od &lt; 50 kopija/ml.
At 26 weeks (primary endpoint), Ultibro Breezhaler increased trough FEV1 by 80 ml in patients (Ultibro Breezhaler n=82; placebo n=42) with the lowest degree of reversibility ( &lt; 5%) (p=0.053) and by 220 ml in those patients (Ultibro Breezhaler n=392, placebo n=190) with a higher degree of reversibility at baseline (≥5%) compared to placebo (p &lt; 0.001).
U 26 tjedana (primarni ishod), Ultibro Breezhaler povećao je najniži FEV1 za 80 ml u bolesnika (Ultibro Breezhaler n=82; placebo n=42) s najnižim stupnjem reverzibilnosti ( &lt; 5%) (p=0,053) te za 220 ml u onih bolesnika (Ultibro Breezhaler n=392, placebo n=190) s višim stupnjem reverzibilnosti na početku (≥5%) u usporedbi s placebom (p &lt; 0,001).
At 26 weeks (primary endpoint), Ulunar Breezhaler increased trough FEV1 by 80 ml in patients (Ulunar Breezhaler n=82; placebo n=42) with the lowest degree of reversibility ( &lt; 5%) (p=0.053) and by 220 ml in those patients (Ulunar Breezhaler n=392, placebo n=190) with a higher degree of reversibility at baseline (≥5%) compared to placebo (p &lt; 0.001).
U 26 tjedana (primarni ishod), Ulunar Breezhaler povećao je najniži FEV1 za 80 ml u bolesnika (Ulunar Breezhaler n=82; placebo n=42) s najnižim stupnjem reverzibilnosti ( &lt; 5%) (p=0,053) te za 220 ml u onih bolesnika (Ulunar Breezhaler n=392, placebo n=190) s višim stupnjem reverzibilnosti na početku (≥5%) u usporedbi s placebom (p &lt; 0,001).
At 26 weeks (primary endpoint), Xoterna Breezhaler increased trough FEV1 by 80 ml in patients (Xoterna Breezhaler n=82; placebo n=42) with the lowest degree of reversibility ( &lt; 5%) (p=0.053) and by 220 ml in those patients (Xoterna Breezhaler n=392, placebo n=190) with a higher degree of reversibility at baseline (≥5%) compared to placebo (p &lt; 0.001).
U 26 tjedana (primarni ishod), Xoterna Breezhaler povećao je najniži FEV1 za 80 ml u bolesnika (Xoterna Breezhaler n=82; placebo n=42) s najnižim stupnjem reverzibilnosti ( &lt; 5%) (p=0,053) te za 220 ml u onih bolesnika (Xoterna Breezhaler n=392, placebo n=190) s višim stupnjem reverzibilnosti na početku (≥5%) u usporedbi s placebom (p &lt; 0,001).
At 28 weeks, treatment with once weekly Trulicity 1.5 mg resulted in a statistically significant reduction in HbA1c compared to placebo and a significantly greater percentage of patients achieving HbA1c targets of &lt; 7.0 % and ≤ 6.5 % (Table 8).
U 28. tjednu, liječenje lijekom Trulicity 1,5 mg jedanput na dan dovelo je do statistički značajnog smanjenja razine HbA1c u usporedbi s placebom te značajno većeg postotka bolesnika koji su postigli ciljnu vrijednost HbA1c od &lt; 7,0% i ≤ 6,5% (Tablica 8).
At 3 years, LEMTRADA reduced the risk of 6-month SAD by 76% (hazard ratio 0.24 [95% CI: 0.110, 0.545], p &lt; 0.0006) and reduced the ARR by 67% (rate ratio 0.33 [95% CI: 0.196, 0.552], p &lt; 0.0001) as compared to subcutaneous IFNB-1a.
Nakon 3 godine LEMTRADA je smanjila rizik od 6-mjesečnog SAD-a za 76% (omjer hazarda 0,24 [95% CI: 0,110, 0,545], p &lt; 0,0006) i ARR-a za 67% (omjer udjela 0,33 [95% CI: 0,196, 0,552], p &lt; 0,0001) u usporedbi sa supkutano primijenjenim IFNB-1a.
At 4 hours post first dose, there was a significant difference in the mean percentage change from baseline plasma uric acid concentration (p &lt; 0.0001) in the Fasturtec group (- 86.0%) compared to that for the allopurinol group (-12.1%).
4 sata nakon primjene prve doze zabilježena je značajna razlika u prosječnom postotku promjene koncentracije mokraćne kiseline u plazmi u odnosu na početnu (p &lt; 0,0001) u skupini koja je primala Fasturtec (-86,0%), u usporedbi sa skupinom koja je primala alopurinol (-12,1%).
At 48 weeks of treatment the emtricitabine-containing regimen demonstrated an equivalent proportion of patients with HIV RNA &lt; 400 copies/ml (94% emtricitabine versus 92%) and a greater proportion of patients with HIV RNA &lt; 50 copies/ml (95% emtricitabine versus 87%) compared with the patients continuing with their PI-HAART regimen.
Nakon 48 tjedana terapije, terapija emtricitabinom je pokazala ekvivalentan udio pacijenata s HIV RNK &lt; 400 kopija/ml (94% u skupini emtricitabina naspram 92% u PI-HAART) te veći udio pacijenata s HIV RNK &lt; 50 kopija/ml (95% za emtricitabin naspram 87% za PI-HAART) u usporedbi s pacijentima koji su nastavili terapiju PI-HAART-om.
At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA &lt; 50 copies/ml with the once and twice daily regimens of lopinavir/ritonavir, respectively.
U 48. tjednu je 70% odnosno 64% bolesnika ostvarilo HIV-1 RNK &lt; 50 kopija/ml uz režim doziranja lopinavira/ritonavira jedanput odnosno dvaput na dan.
At 48 weeks, 70% and 64% of patients demonstrated HIV-1 RNA &lt; 50 copies/mL with the once and twice daily regimens of lopinavir/ritonavir, respectively.
U 48. tjednu je 70% odnosno 64% pacijenata pokazalo HIV-1 RNK &lt; 50 kopija/mL uz režim doziranja lopinavira/ritonavira jedanput odnosno dvaput na dan.
At 48 weeks, 92% (46/50) achieved HIV-1 RNA &lt; 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults.
U 48. tjednu, njih 92% (46/50) postiglo je HIV-1 RNK &lt; 50 kopija/ml, što je slično stopama odgovora u ispitivanjima odraslih bolesnika zaraţenih virusom HIV-1 koji prethodno nisu bili liječeni.
At 48 weeks, 92% (46/50) achieved HIV-1 RNA &lt; 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults.
U 48. tjednu, njih 92% (46/50) postiglo je HIV-1 RNK &lt; 50 kopija/ml, što je slično stopama odgovora u ispitivanjima odraslih bolesnika zaraženih virusom HIV-1 koji prethodno nisu bili liječeni.
At 5 years, LEMTRADA reduced the risk of SAD by 69% (hazard ratio 0.31 [95% CI: 0.161, 0.598], p=0.0005) and reduced the ARR by 66% (rate ratio 0.34 [95% CI: 0.202, 0.569], p &lt; 0.0001) as compared to subcutaneous IFNB-1a.
Nakon 5 godina LEMTRADA je smanjila rizik od SAD-a za 69% (omjer hazarda 0,31 [95% CI: 0,161, 0,598], p=0,0005) i ARR-a za 66% (omjer udjela 0,34 [95% CI: 0,202, 0,569], p &lt; 0,0001) u usporedbi sa supkutano primijenjenim IFNB-1a.
At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p &lt; 0.001).
U 54. je tjednu klinički odgovor imalo 44,9% bolesnika u objema skupinama liječenima infliksimabom, u odnosu na 19,8% ispitanika u skupini koja je primala placebo (p &lt; 0,001).
At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p &lt; 0.001).
U 54. je tjednu klinički odgovor imalo 44,9% bolesnika u objema skupinama liječenima infliksimabom, u odnosu na19,8% ispitanika u skupini koja je primala placebo (p &lt; 0,001).
At 6 months after the last dose, the median reductions in B cell counts were &gt; 99% for ofatumumab in combination with chlorambucil and 94% for chlorambucil alone.
Šest mjeseci nakon posljednje doze medijan smanjenja broja B-stanica iznosio je &gt; 99% za ofatumumab u kombinaciji s klorambucilom te 94% za monoterapiju klorambucilom.
At 6 months, patients treated with Soliris with no history of RBC transfusion had significantly (p &lt; 0.001) reduced LDH levels (median LDH of 305 U/L; Table 4).
Nakon 6 mjeseci, bolesnici liječeni lijekom Soliris koji nikad nisu primili transfuziju eritrocita imali su značajno (p &lt; 0,001) snižene razine LDH (medijan LDH od 305 U/l; tablica 4).
At 96 weeks, the proportion of patients with &lt; 50 HIV-1 RNA copies/ml receiving rilpivirine 25 mg (N=93) compared to patients receiving efavirenz (N=89) was 76% and 71%, respectively.
U 96 tjedana, udio bolesnika s &lt; 50 HIV-1 RNK kopija/ml koji su primali rilpivirin od 25 mg (N = 93) iznosio je 76%, a udio bolesnika koji su primali efavirenz (N = 89) iznosio je 71%.
At a dose of 20 mg Levitra film-coated tablets, elderly ( 65 years old) patients had higher frequencies of headaches (16.2% versus 11.8%) and dizziness (3.7% versus 0.7%) than younger patients ( &lt; 65 years old).
Uz Levitra filmom obložene tablete od 20 mg, stariji (u dobi od ≥ 65 godina) bolesnici imali su veću učestalost glavobolja (16,2% nasuprot 11,8%) i omaglice (3,7% nasuprot 0,7%) nego mlađi bolesnici (u dobi od &lt; 65 godina).
At a rate of rise in haemoglobin of &gt; 2 g/dl ( &gt; 1.25 mmol/l) per month the Retacrit dose should be reduced by about 25-50%.
Kod porasta hemoglobina za &gt; 2 g/dl ( &gt; 1,25 mmol/l) mjesečno, potrebno je smanjiti dozu Retacritom za 25-50%.
At a rate of rise in haemoglobin of &gt; 2 g/dl ( &gt; 1.25 mmol/l) per month the Silapo dose should be reduced by about 25-50%.
Kod porasta hemoglobina za &gt; 2 g/dl ( &gt; 1,25 mmol/l) mjesečno, potrebno je smanjiti dozu Silapom za 25-50%.
At a single tested, relatively low, maternal dose of 30 mg/kg, the concentration of foetal radioactivity was ≤ 27% of the maternal concentration.
U jednoj testiranoj, relativno niskoj dozi za majke od 30 mg/kg, koncentracija fetalne radioaktivnosti iznosila je &lt; 27% koncentracije u majke.
At a very high dose ( &gt; 240 times the recommended daily human maintenance dose on a mg/m2 basis) that caused effects on maternal body weight and/or food consumption, there was a slight decrease in offspring body weight (relative to controls).
Pri vrlo visokim dozama ( &gt; 240 puta većima od preporučene dnevne doze održavanja u ljudi na temelju mg/m2) koje su imale učinak na maternalnu tjelesnu težinu i/ili unos hrane, opaženo je malo smanjenje tjelesne težine potomaka (u odnosu na kontrolnu skupinu).
At all post-dose time points on day 8, the mean changes from baseline in QTcF interval were 4 - 6 msec, with associated upper 95% confidence intervals &lt; 7 msec.
U svim vremenskim točkama nakon doze 8. dana, prosječna promjena u duljini QTcF intervala u odnosu na početnu iznosila je 4 -6 msek, uz gornju granicu 95% raspona pouzdanosti od &lt; 7 msek.
At all post-injection days, p≤0.024 in TG-MV-006, p≤0.009 in TG-MV-007, p &lt; 0.001 in integrated data
U sv im danima nakon injekcije p≤0.024 u TG-MV-006, p≤0.009 u TG-MV-007, p &lt; 0.001 u integriranim podacima
At baseline 52% of patients had high disease activity (SELENA SLEDAI score &gt; 10), 59% of patients had mucocutaneous, 60% had musculoskeletal, 16% had haematological, 11% had renal and 9% had vascular organ domain involvement (BILAG A or B at baseline).
Na početku ispitivanja je 52% bolesnika imalo visoki stupanj aktivnost bolesti (SELENA SLEDAI rezultat &gt; 10), u 59% bolesnika zahvaćene su bile koža i sluznice, u 60% bolesnika mišićno-koštani sustav, u 16% hematološki sustav, u 11% bubrezi, te u 9% vaskularni sustav (BILAG A ili B ishodišno).
At baseline entecavir-treated patients had a median duration of prior lamivudine therapy of 4.8 years and median CD4 count of 494 cells/mm3 (with only 5 subjects having CD4 count &lt; 200 cells/mm3).
Na početku ispitivanja, bolesnici liječeni entekavirom imali su medijan trajanja prethodne terapije lamivudinom od 4,8 godina i medijan broja CD4 od 494 stanica/mm3 (sa samo 5 ispitanika s brojem CD4 &lt; 200 stanica/mm3).
At baseline, 80 patients (33%) had eGFRCG &lt; 50 mL/min and 162 patients had eGFRCG ≥ 50 mL/min.
Na početku je 80 bolesnika (33%) imalo eGFRCG &lt; 50 ml/min, a 162 bolesnika su imala eGFRCG  50 ml/min.
At concentrations substantially higher ( &gt; 4,000-fold) than those observed in vivo, adefovir did not inhibit any of the following human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.
Pri koncentracijama znatno višima ( &gt; 4000 puta) od onih primijećenih in vivo, adefovir nije inhibirao niti jedan od sljedećih izooblika humanog CYP450: CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.
At Day 15, the treatment difference between lumacaftor 400 mg/ivacaftor 250 mg q12h and placebo for the mean absolute change (95% CI) in ppFEV1 from baseline was 2.51 percentage points in the pooled Trials 1 and 2 (P &lt; 0.0001).
U objedinjenim ispitivanjima 1 i 2, terapijska razlika između lumakaftora 400 mg/ivakaftora 250 mg svakih 12 sati i placeba za srednju vrijednost apsolutne promjene (95% CI) u ppFEV1 iznosila je 15. dana u odnosu na početnu vrijednost 2,51 postotnih bodova (P &lt; 0,0001).
At day 42, 100% of subjects aged 18-60 years and 96.4% of subjects aged &gt; 60 years had a titre of at least 1:80.
Četrdeset i drugog dana, 100% ispitanika od 18 do 60 godina, te 96,4% ispitanika starijih od 60 godina imalo je titar od najmanje 1:80.
At day 57, patients treated with Picato had higher complete and partial clearance rates than patients treated with vehicle gel (p &lt; 0.001).
U 57. danu bolesnici liječeni lijekom Picato imali su više stope potpunog i djelomičnog nestanka nego bolesnici liječeni podlogom gela (p &lt; 0,001).
At Day 9 the incidence of major bleeding on fondaparinux and enoxaparin was 2.1% and 4.1%, respectively (hazard ratio 0.52, 95% CI, 0.44;0.61, p &lt; 0.001).
Deveti dan je incidencija velikog krvarenja iznosila 2,1% na fondaparinuksu, odnosno 4,1% na enoksaparinu (omjer rizika 0,52; 95% CI, 0,44; 0,61, p &lt; 0,001).
At doses &gt; 400 mg/day, half-lives of 3 to 10 hours have been reported.
Pri dozama &gt; 400 mg/dan prijavljen je poluvijek od 3 do 10 sati.
At doses ≥ 500 mg per dose or &lt; 3 g per day, precautions are required due to increased risk of haemorrhage, ulcerations and gastro-intestinal perforation.
Pri dozama ≥ 500 mg po dozi ili &lt; 3 g na dan potrebno je poduzeti mjere opreza zbog povećanog rizika od krvarenja, ulceracija i gastrointestinalne perforacije.